AL-102 is under clinical development by Immunome and currently in Phase III for Benign Tumor. According to GlobalData, Phase III drugs for Benign Tumor have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how AL-102’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AL-102 overview

AL-102 (formerly BMS-986115) is under development for the treatment of desmoid tumors, relapsed and refractory T-cell acute lymphoblastic leukemia (T-ALL) and relapsed/refractory multiple myeloma. It is administered orally. The drug candidate is a pan-notch gamma secretase inhibitor.

It was under development for the treatment of advanced solid tumors

Immunome overview

Immunome is a biopharmaceutical company that discovers and develops antibodies based on drugs to treat infectious diseases. It is investigating IMM-ONC-01 drug that targets IL-38 (interleukin-38) for the treatment of solid tumors found in prostate, colorectal and lung cancers; and IMM-BCP-01, an anti-infective drug targeting multiple SARS-Cov-2 proteins. The company utilizes its immunome discovery platform to develop antibodies. It seeks to work in partnership with pharmaceutical companies, government agencies, universities and global health organizations to develop new treatments. Immunome is headquartered in Exton, Pennsylvania, the US.

For a complete picture of AL-102’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.